| Identification | Back Directory | [Name]
Tricyclo[3.3.1.13,7]decan-1-amine, N-[4-[(1S,3S)-3-butyl-1,2,3,4-tetrahydro-6-methoxy-1-isoquinolinyl]phenyl]- | [CAS]
2485005-22-7 | [Synonyms]
GPX4-IN-2
Tricyclo[3.3.1.13,7]decan-1-amine, N-[4-[(1S,3S)-3-butyl-1,2,3,4-tetrahydro-6-methoxy-1-isoquinolinyl]phenyl]- | [Molecular Formula]
C30H40N2O | [MOL File]
2485005-22-7.mol | [Molecular Weight]
444.65 |
| Chemical Properties | Back Directory | [Boiling point ]
590.6±50.0 °C(Predicted) | [density ]
1.109±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.67±0.60(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
GPX4-IN-2 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-2 has the potential for the research of cancer[1]. | [in vivo]
GPX4-IN-2 (5 mg/kg for mouse, 2 mg/kg for rats; i.v.) shows a good pharmacokinetics profile in mice and rats[1]. | Animal Model: | 6-8 weeks, 22-25 g, Male Balb/c mice, 6-8 weeks, 200-250 g, male SD rats[1] | | Dosage: | 5 mg/kg for mouse, 2 mg/kg for rats | | Administration: | I.v. | | Result: | Showed a good pharmacokinetics with T1/2 of 3.5 h, Cmax of 5446 ng/mL, AUC of 1635 ng·h/mL, CL of 49 mL/min/kg, Vd of 14.7 L/kg in mice, T1/2 of 3.15 h, Cmax of 3529 ng/mL, AUC of 1082 ng·h/mL, CL of 30 mL/min/kg, Vd of 8.2 L/kg in rats. |
| [References]
[1] Chun Jiang, et al. Compounds with ferroptosis inducing activity and methods of their use. WO2020176757A1. |
|
|